XNYS
JNJ
Market cap649bUSD
Sep 21, Last price
269.47USD
1D
-0.19%
1Q
12.71%
Jan 2017
133.89%
Name
Johnson & Johnson
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Johnson & Johnson functions as a global healthcare enterprise, involved in the research, development, manufacturing, and commercialization of a wide spectrum of health-related products. Its activities are organized across three principal divisions: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment provides an extensive range of goods, encompassing baby care items under brands like JOHNSON'S and AVEENO Baby, oral hygiene products such as LISTERINE, and skin/beauty solutions from AVEENO, NEUTROGENA, and OGX. It also offers over-the-counter medications for various ailments, including pain relief (TYLENOL, MOTRIN IB), cold, flu, and allergy symptoms (SUDAFED, BENADRYL, ZYRTEC), smoking cessation aids (NICORETTE), and acid reflux treatments (PEPCID). Additionally, this division includes women's health products like STAYFREE and o.b., wound care essentials such as BAND-AID adhesive bandages, and NEOSPORIN for first aid. The Pharmaceutical segment is dedicated to developing therapies within significant therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic disorders. The Medical Devices segment delivers sophisticated solutions for cardiovascular conditions, including electrophysiology and neurovascular care for strokes. It also provides orthopaedic products supporting hips, knees, trauma, spine, and sports-related needs, alongside advanced and general surgical solutions focusing on breast aesthetics and ear, nose, and throat procedures. Furthermore, this segment offers ophthalmic products, notably ACUVUE brand disposable contact lenses and technologies for cataract and laser refractive surgery. The company distributes its products through diverse channels, reaching the general public via retail outlets and distributors, and directly supplying wholesalers, hospitals, and healthcare professionals for prescription-based use. Johnson & Johnson was established in 1886 and maintains its headquarters in New Brunswick, New Jersey.
Related entities
Subsidiaries (205)
MEDICAL DEVICE BUSINESS SERVICES, INC.
MEGADYNE MEDICAL PRODUCTS, INC.
NEURAVI LIMITED
NEUWAVE MEDICAL, INC.
ORTHOTAXY
PT JOHNSON AND JOHNSON INDONESIA TWO
SHANGHAI HI MOTHER AND BABY PRODUCTS INTERNATIONAL TRADE CO., LTD
SHANGHAI JOHNSON & JOHNSON LTD.
SHANGHAI JOHNSON & JOHNSON PHARMACEUTICALS LTD.
SterilMed, Inc.
SYNTHES USA PRODUCTS, LLC
TARIS BIOMEDICAL LLC
TORAX MEDICAL, INC.
VISION CARE FINANCE UNLIMITED COMPANY
XIAN JANSSEN PHARMACEUTICAL LTD.
强生(中国)有限公司
Abiomed Europe GmbH
Abiomed Japan K.K.
Key people
Chairman of the Board, Chief Executive Officer · since 2012
Vice Chairman - Executive Committee · since 2018
Peter M. Fasolo
Chief Human Resource Officer, Executive Vice President · since 2016
Executive Vice President - Worldwide Chairman, Medical Devices · since 2018
Thibaut Mongon
Executive Vice President, Worldwide Chairman, Consumer · since 2018
Jennifer L. Taubert
Executive Vice President - Worldwide Chairman, Pharmaceuticals · since 2018
Michael H. Ullmann
Executive Vice President, General Counsel · since 2016
Kathryn E. Wengel
Executive Vice President, Chief Global Supply Chain Officer · since 2018
Joseph J. Wolk
Chief Financial Officer, Executive Vice President · since 2018
Vice Chairman- Executive Committee, Chief Scientific Officer · since 2018
Lead Independent Director · since 2012
Independent Director · since 2015
Independent Director · since 2010
Independent Director · since 2016
Jennifer A. Doudna
Independent Director · since 2018
A. Eugene Washington
Independent Director · since 2012
Headquarters & legal address
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
US
New Brunswick, NJ 08933
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑00 | 2021‑00 | 2019‑12 | 2019‑12 | 2018‑12 | 2018‑12 | 2017‑12 | 2017‑00 | 2016‑12 | |
| Income | |||||||||||||
Revenues | |||||||||||||
Cost of revenue | |||||||||||||
Unusual Expense (Income) | |||||||||||||
NOPBT | |||||||||||||
NOPBT Margin | |||||||||||||
Operating Taxes | |||||||||||||
Tax Rate | |||||||||||||
NOPAT | |||||||||||||
Net income | |||||||||||||
Dividends | |||||||||||||
Dividend yield | |||||||||||||
Proceeds from repurchase of equity | |||||||||||||
BB yield | |||||||||||||
| Debt | |||||||||||||
Debt current | |||||||||||||
Long-term debt | |||||||||||||
Deferred revenue | |||||||||||||
Other long-term liabilities | |||||||||||||
Net debt | |||||||||||||
| Cash flow | |||||||||||||
Cash from operating activities | |||||||||||||
CAPEX | |||||||||||||
Cash from investing activities | |||||||||||||
Cash from financing activities | |||||||||||||
FCF | |||||||||||||
| Balance | |||||||||||||
Cash | |||||||||||||
Long term investments | |||||||||||||
Excess cash | |||||||||||||
Stockholders' equity | |||||||||||||
Invested Capital | |||||||||||||
ROIC | |||||||||||||
ROCE | |||||||||||||
| EV | |||||||||||||
Common stock shares outstanding | |||||||||||||
Price | |||||||||||||
Market cap | |||||||||||||
EV | |||||||||||||
EBITDA | |||||||||||||
EV/EBITDA | |||||||||||||
Interest | |||||||||||||
Interest/NOPBT | |||||||||||||